Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics

BOSTON & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen’s antibody discovery platforms through a strategic investment. In turn, Propeller wi

administrator

Related Articles